nutch_noindex
CANCEL
/nutch_noindex

Michelle Goldsmith, MD

  • Michelle Dana Goldsmith

Specialties

Psychiatry

Work and Education

Professional Education

Drexel University College of Medicine, Philadelphia, PA, 6/2004

Residency

University of Pennsylvania School of Medicine, Philadelphia, PA, 06/2008

Fellowship

Stanford University School of Medicine, Stanford, CA, 6/2010

Board Certifications

Child & Adolescent Psychiatry, American Board of Psychiatry and Neurology

Psychiatry, American Board of Psychiatry and Neurology

All Publications

Preparing and Training the College Mental Health Workforce. Academic psychiatry Riba, M., Kirsch, D., Martel, A., Goldsmith, M. 2015; 39 (5): 498-502

View details for DOI 10.1007/s40596-015-0406-x

View details for PubMedID 26307363

Medical student education in psychiatry: an international affair. Academic psychiatry Goldsmith, M., Bryden, P. 2014; 38 (3): 361-363

View details for DOI 10.1007/s40596-014-0120-0

View details for PubMedID 24789480

Ethical Considerations in Child and Adolescent Psychiatry Focus: The Journal of Lifelong Learning in Psychiatry Michelle D. Goldsmith, Shashank V. Joshi 2012; X (2): 315
Antidepressants and Psychostimulants in Pediatric Populations Is there an Association with Mania? PEDIATRIC DRUGS Goldsmith, M., Singh, M., Chang, K. 2011; 13 (4): 225-243

Abstract

This article reviews the literature that examines whether exposure to psychostimulants or antidepressants precipitates or exacerbates manic symptoms, or decreases the age at onset of mania in pediatric populations. A PubMed search using relevant key words identified studies targeting five distinct clinical groups: (i) youth without a diagnosis of bipolar disorder (BD) at the time of exposure to psychostimulants; (ii) youth with a diagnosis of BD at the time of exposure to psychostimulants; (iii) youth without a diagnosis of BD at the time of exposure to antidepressants; (iv) youth with a diagnosis of BD at the time of exposure to antidepressants; and (v) youth who develop BD after exposure to these medications. In patients with attention-deficit hyperactivity disorder (ADHD), the risk for mania was found to be relatively low with the use of psychostimulants. For patients with BD and ADHD, effective mood stabilization is important prior to adding a stimulant. For children with depression and/or anxiety, the risk of antidepressant-induced mania (AIM) was generally low (<2%), but the risk of general 'activation' secondary to a selective serotonin reuptake inhibitor (SSRI) may be greater (2-10%). However, rates of AIM in specialty clinics appear to be much higher. SSRIs may be particularly problematic in specific populations, such as those with some symptoms of mania or a family history of BD, but the precise risk is unknown. There is no clear evidence that stimulants or SSRIs accelerate the natural course of BD development in overall samples, but in individual cases prescribers should proceed cautiously when using these agents in youth already at risk for developing BD, such as those with ADHD and mood dysregulation, a history of prior AIM, a history of psychosis, or a family history of BD.

View details for Web of Science ID 000292996000004

View details for PubMedID 21692547